Re “Therapies That Can Attack Cancer, and Organs” (NY Times, front page, Dec.4):
There is a very effective immunotherapy for cancer, which has no significant side effects. This is an off-label use of the inexpensive generic medication naltrexone (the pure anti-narcotic medication) taken at just 4.5mg nightly for cancer, HIV or autoimmune diseases, rather than at the daily 50mg approved by the FDA for heroin addiction and alcoholism recidivism. Specialists using low dose naltrexone (LDN) for cancer report that over 50% of patients show a marked reduction in further progression.
As a generic, naltrexone is made by many companies. Therefore, clinical research on LDN is not in the interest of any big pharma — since an important return on its investment is unlikely. Therefore, no large studies have been done. Thus, no reports in the best medical journals, and no media attention.
You may well not have heard of LDN. Nonetheless, although nobody makes any money from LDN, grateful patients with autoimmune disorders (e.g., Crohn’s disease, MS, Fibromyalgia) have supported smaller studies on LDN at some major research medical centers (e.g., Penn State, UCSF, Stanford) and the results have always shown LDN to be efficacious and entirely safe. You can see the abstracts of all clinical research on my website, www.ldninfo.org.
All autoimmune disorders rely on a weak, dysfunctional immune system (otherwise, the immune system could not attack “self”) and LDN acts (by causing a marked improvement in daily endorphin levels) to normalize one’s immune system.
Since LDN has but one contraindication to its use (i.e., do not take it if dependent on narcotics), one can use it freely with any other medications. LDN is non-toxic and has no significant side effects.
In any cases of advanced cancer, I have always suggested consultation with Dr. Burton Berkson, MD, PhD, who has already published 3 medical journal articles re: a number of patients who had far-advanced cancers and who went into prolonged remissions through his treatment, which involves both oral LDN and IV alpha-lipoic acid (given 2 or 3 times a week) — neither therapy, when used correctly, has any significant side effects. He spoke at a Nat’l Cancer Institute meeting re: LDN in March 2012. He awaits publication of his new paper on the reversal of a metastatic renal cell carcinoma.
His contact #’s:
Burton M Berkson MD, MS, PhD Tel: 1–575–524–3720
1155 Commerce Drive; Las Cruces, New Mexico 88011
Emails: email@example.com, firstname.lastname@example.org
Dr Berkson’s affiliations:
· Adjunct Professor, New Mexico State University
· Mushroom Poisoning Consultant, New Mexico Poison Control Center, UNM
· Acute Hepatic Necrosis Consultant and Thioctic Acid (alpha-lipoic acid),
David (nmi) Gluck, MD